Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics

Asthma Clinical Trial

— BOREAS  

Official title:

A Prospective, Active-controlled, Randomized, Open Label, Single-center, Multiple Dose, Crossover Clinical Trial to Assess the Efficacy, Safety and PK of AQ001S Compared to a Budesonide Inhalation Suspension in Adults With Mild Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04933383
• Other study ID #: AQ-PRO-005
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 23, 2021
• Est. completion date: January 31, 2023

Study information

• Verified date: June 2023
• Source: Aquilon Pharmaceuticals S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the efficacy, safety and pharmacokinetics of AQ001S compared to a budesonide inhalation suspension (comparator) in adults with mild asthma.

Both treatments will be administered by nebulization.

Description:

Adults patients with mild asthma (18 to 65 years old), who are 'inhaled corticosteroid (ICS)'-naïve for minimum 60 days at Screening Visit will be enrolled in the study. The patients will be treated for 28 days. The primary endpoint will be assessed by a provocative concentration of methacholine that results in a 20% drop (PC20) in the first second forced expiratory volume (FEV1) as determined by methacholine challenge test. The pharmacokinetics (PK) endpoint, i.e. PK profile of budesonide in plasma, and pharmacodynamics (PD) endpoints, i.e. recording of symptom scores, use of reliever drugs as needed, biomarkers of airway inflammation and pulmonary function tests will be assessed during the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: January 31, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Body mass index between 18.5 and 29 kg/m2.

• Documented clinical diagnosis of stable, persistent, asthma for at least 3 months

• Subjects who are ICS-naïve for minimum 60 days at Screening Visit.

• Positive methacholine (MCh) challenge test (concentration of MCh provoking an FEV1 fall of 20% [PC20] < 8 mg/ml or dose of MCh provoking an FEV1 fall of 20% [PD20] < 0.2 mg) in the last year.

• Post-bronchodilator FEV1 at least 80% of the predicted, documented in the last year.

• Clinical laboratory test results, 12-lead electrocardiogram (ECG), blood pressure and heart rate (supine) within normal reference range or judged to be not clinically significant by the Investigator.

• Female subjects of childbearing potential should have a negative pregnancy test at Screening Visit and use a highly effective method of contraception.

• Reliable subjects who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures.

• Subjects who have the ability to understand the requirements of the clinical trial.

• Subjects who have given written informed consent.

Exclusion Criteria:

• Current smokers or recent (< 8 weeks) ex-smokers or ex-smokers if > 10 pack-years.

• Pregnant or breastfeeding female subjects.

• Inability to carry out pulmonary function testing.

• FEV1 < 70%.

• History of near-fatal asthma and/or intensive care unit admission for asthma symptoms.

• Exacerbations of asthma requiring oral steroids, hospitalization or change in asthma treatment in the previous three months.

• Evidence of symptomatic chronic or acute respiratory infection in the previous 8 weeks.

• Diagnosis of chronic obstructive pulmonary disease (COPD) or bronchiectasis.

• Pulmonary malformations, tuberculosis, cystic fibrosis.

• History of hypersensitivity or existing contraindication to budesonide or any other Investigational Medicinal Product (IMP) ingredients.

• Untreated oral candidiasis.

• Immunosuppressive treatment, including systemic corticosteroids (e.g., oral, parenteral, ocular, nasal), within 28 days before Screening Visit.

• Use of ICS within 60 days before Screening Visit.

• Use of anti-leukotrienes, immunoglobulins, beta-blockers, digitalis, amiodarone, antifungals, macrolides, antidepressants, monoamine oxidase inhibitors, antiretroviral drugs, cholinesterase inhibitors, histamine, theophylline, non-steroidal anti-inflammatory drugs, anticholinergic drugs, neuroleptics, curariform drugs, antihistaminic (anti-H1) drugs, calcium channel blockers, long acting beta2-antagonists, mast cell stabilizers (e.g. natrium cromoglycate).

• History of alcohol or drug abuse.

• Unstable or life-threatening cardiac disease

• History or presence of prolonged QT interval (> 470 ms), or any other clinically significant ECG abnormalities as judged by the Investigator based on 12-lead ECG recordings at Screening Visit.

• Diabetes mellitus.

• Neuropsychiatric diseases.

• Clinically relevant laboratory abnormalities at Screening Visit.

• Blood or plasma donation within 30 days prior to Screening Visit.

• History or presence of malignancy of any system organ class (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior to Screening Visit, regardless of whether there is evidence of local recurrence or metastases.

• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the clinical trial.

• History or presence of any other clinically relevant disease of any major system organ class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive, endocrinological, neurological, psychiatric or orthopedic disease) as judged by the Investigator.

• Human immunodeficiency virus (HIV) and severe acute respiratory syndrome (SARS)-CoV-2 infections.

• Subjects who participated in an investigational trial within the 12 weeks prior to the start of the trial.

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• AQ001S 0.125 mg/ml
administered by nebulization once daily
• Budesonide 0.125 mg/ml inhalation suspension
administered by nebulization once daily

Locations

Country	Name	City	State
Belgium	Pneumocare SPRL	Erpent	Namur

Sponsors (1)

Lead Sponsor	Collaborator
Aquilon Pharmaceuticals S.A.

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in PC20 assessed by methacholine (MCh) challenge test	At Visit 1 (baseline), Visit 2 (28-day treatment period 1) and Visit 4 (28-day treatment period 2), a MCh challenge test will be performed, i.e. up to the administration of a concentration of MCh provoking an FEV1 fall of 20% (PC20). FEV1 is measured by spirometry. The change in PC20 from baseline to the end of each period (two periods) will be assessed.	At the end of Period 1 and end of Period 2 (each period is 29 days)
Primary	Incidence of Treatment-Emergent Adverse Events	Incidence of Treatment-Emergent Adverse Events as assessed by collection of (Serious) Adverse Events, general and local tolerability and hypothalamic-pituitary-adrenal (HPA) axis function	Over the treatment period, up to 29-day treatment period
Secondary	Change in FeNO measurements	Fractional exhaled nitric oxide (FeNO) measurements at Visit 1 (baseline), Visit 2 (treatment period 1) and Visit 4 (treatment period 2)	At the end of Period 1 and Period 2 (each period is 29 days)
Secondary	Change in blood eosinophil counts	Blood eosinophil counts at Visit 1 (baseline), Visit 2 (treatment period 1) and Visit 4 (treatment period 2)	At the end of Period 1 and Period 2 (each period is 29 days)
Secondary	Asthma symptoms	Day- and night-time of asthma symptoms over the treatment periods	29-day treatment period
Secondary	Single dose budesonide levels in plasma	Budesonide PK level in plasma measured at Visit 1 (baseline) and following the first single dose treatment	1-day treatment
Secondary	Budesonide levels in plasma	Budesonide PK level in plasma measured at Visit 2 (end of treatment period 1) and Visit 4 (end of treatment period 2). Blood samples will be performed at pre-dose and at 10, 20, 45, 120, 240 and 360 minutes after IMP administration (abridged PK).	At Day 28 of Period 1 and at Day 28 of Period 2